Quick Answer
SANGAMO THERAPEUTICS, INC reported Operating Income Loss of -$121.24 million for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -16.6% in Operating Income Loss from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), SANGAMO THERAPEUTICS, INC's Operating Income Loss has declined by 524.9%.
- Historical annual values: Fiscal year 2025: -$121.24 million | Fiscal year 2024: -$103.97 million | Fiscal year 2023: -$274.01 million | Fiscal year 2022: -$201.28 million | Fiscal year 2021: -$183.34 million | Fiscal year 2020: -$129.55 million | Fiscal year 2019: -$105.18 million | Fiscal year 2018: -$77.15 million | Fiscal year 2017: -$56.36 million | Fiscal year 2016: -$72.56 million | Fiscal year 2015: -$46.86 million | Fiscal year 2014: -$26.78 million | Fiscal year 2013: -$26.71 million | Fiscal year 2012: -$22.20 million | Fiscal year 2011: -$35.82 million | Fiscal year 2010: -$24.94 million | Fiscal year 2009: -$19.40 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: